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Abstract
Background: Recent advances toward an effective therapy for prion diseases employ RNA interference to suppress PrP
C
expression and subsequent prion neuropathology, exploiting the phenomenon that disease severity and progression
correlate with host PrP
C expression levels. However, delivery of lentivirus encoding PrP shRNA has demonstrated only
modest efficacy in vivo.
Methodology/Principal Findings: Here we describe a new siRNA delivery system incorporating a small peptide that binds
siRNA and acetylcholine receptors (AchRs), acting as a molecular messenger for delivery to neurons, and cationic liposomes
that protect siRNA-peptide complexes from serum degradation.
Conclusions/Significance: Liposome-siRNA-peptide complexes (LSPCs) delivered PrP siRNA specifically to AchR-expressing
cells, suppressed PrP
C expression and eliminated PrP
RES formation in vitro. LSPCs injected intravenously into mice resisted
serum degradation and delivered PrP siRNA throughout the brain to AchR and PrP
C-expressing neurons. These data
promote LSPCs as effective vehicles for delivery of PrP and other siRNAs specifically to neurons to treat prion and other
neuropathological diseases.
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Introduction
The transmissible spongiform encephalopathies (TSEs), or prion
diseases, are invariably fatal neurodegenerative disorders affecting
primarily sheep (Scrapie), cattle (bovine spongiform encephalop-
athy), cervids (chronic wasting disease (CWD)) and humans
(Creutzfeldt-Jakob and fatal familial insomnia). The prion
hypothesis asserts that TSEs are caused by a misfolded, protease
resistant isoform (PrP
RES) of a cellular prion protein (PrP
C) that is
present on many mammalian cells but most highly expressed on
neurons and glial cells in the central nervous system (CNS,
[1,2,3]). Prions travel from peripheral infection sites to the CNS
where they cause conformational changes in PrP
C to form PrP
RES,
and pathological changes in neural tissue including progressive
neuronal cell death and gliosis [4,5,6,7]. Presently, no effective
therapies have been developed to treat TSEs.
An interesting aspect of prion diseases that researchers currently
exploit as a therapeutic target is the necessity of PrP
C expression
on CNS neurons for disease progression [8,9,10]. Decreasing
neuronal PrP
C expression in scrapie-infected mice decreases
incidence and severity, delays development [11,12,13] and can
even reverse neuropathology of prion diseases [14]. The two most
recent of these studies used RNA interference (RNAi), a relatively
new tool for silencing specific genes in biological systems
[15,16,17,18] to decrease PrP
C within the CNS. RNAi has been
shown to be potentially useful in treating several diseases including
hepatitis [19,20], cancer [21], ocular disorders [22] and chronic
pain [23].
RNAi was first shown to effectively knock down PrP
C expression
in cells transfected with PrP-encoding plasmids [24]. The same
group later demonstrated efficient PrP
C knockdown in mice
expressing an shRNA transgene, although they did not report
whether these mice were protected from prion disease [25]. In vivo
studies using intracranial (ic) injections of lentiviral vectors
encoding PrP-specific shRNAs to knockdown focal PrP
C expres-
sion [12,13] have shown modest effectiveness experimentally and
limited use clinically due to the invasive delivery method, limited
area and irreversibility of PrP
C suppression and safety concerns.
More recently, Kumar et al have developed a transvascular
method to deliver siRNA across the blood-brain barrier (BBB) to
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complexing siRNA to a short peptide derived from the rabies virus
glycoprotein that binds specifically to acetylcholine receptors
(AchRs) on neuronal cells [27,28]. Adding nine d-Arginines to the
carboxy terminus of this peptide (RVG-9r) enabled it to
electrostatically interact with siRNA and specifically deliver siRNA
to neurons in mouse brains to suppress protein expression and
protect against fatal viral encephalitis. Efficient peptide-mediated
delivery of siRNA to the brain after iv injection relies on protecting
the complex from nuclease and protease degradation en route.
Complexing or encapsulating siRNA with liposomes has been
shown to protect siRNA from degradation and improve delivery
through the vasculature [29,30,31,32,33,34].
In the present study, we demonstrate the ability of cationic
liposomes to protect siRNA from serum degradation and of the
RVG-9r peptide to specifically target these liposome-siRNA-
peptide complexes (LSPCs) to neuronal cells, knockdown PrP
C
expression and greatly decrease PrP
RES in chronically prion-
infected neuronal cells in vitro. Following injection of fluorescent
RVG-9r LSPCs into mice, examination of brain sections indicated
widespread presence of siRNA in the CNS. These data validate
the use of LSPCs to protect siRNAs from serum degradation and
deliver them across the BBB to AchR-expressing neuronal cells
throughout the brain to potentially cure prion and perhaps other
neurodegenerative diseases.
Results
Identification of effective PrP siRNA target sequences
To determine target sequences of the prnp gene at which siRNA
could effectively suppress PrP
C expression, we scanned approxi-
mately 1 kilobase of the 39 untranslated region for siRNA targets
predicted to reduce PrP transcript levels to less than 20% of
normal [35]. We selected three sequences beginning at 1578, 1633
and 1672 bases after the transcriptional start site (table 1 and
figure 1A), constructed plasmids encoding shRNAs targeting these
sequences and a control sequence containing a scrambled 1672
sequence, transfected them into PrP-expressing N2a cells and
analyzed their PrP expression 48 hours later. RT-PCR (figure 1B)
and FACS analyses (figure 1C and D) demonstrate that all three
shRNA plasmids suppressed PrP mRNA and protein levels,
respectively, in a dose-dependent manner, to less than 25% of
normal levels (p,0.01, n=5). We detected no significant change
in PrP mRNA and protein levels in N2a cells transfected with
plasmids encoding no shRNA or scrambled 1672 sequence.
Liposome protection and peptide delivery of PrP siRNA
to neuronal cells
A 29-residue peptide from the rabies virus glycoprotein has
been previously shown to bind acetylcholine receptors (AchRs)
with high affinity and specificity [28]. Addition of nine d-Arginine
residues enabled the peptide, RVG-9r, to bind siRNA and deliver
it specifically to neuronal cells after iv injection to suppress protein
expression and cure Japanese Encephalitis viral infection [26]. We
sought to improve RVG-9r delivery of siRNA by protecting
siRNA-peptide complexes from serum degradation by adding
liposomes. One hundred picomoles of siRNA were complexed
with various concentrations of sonicated and filtered liposomes
then with 1000 pmol of RVG-9r. The resulting liposome-siRNA-
peptide complexes (LSPCs) were 178620 nm in hydrodynamic
diameter with surface charges ranging from 6.2560.75 to
9.7860.96 to 19.8964.46 mV with 10, 100 and 1000 pmol of
liposomes, respectively. LSPCs were incubated in 90% mouse
serum at 37uC and assayed for degradation over time. Addition of
100 pmol of liposomes prevented significant serum degradation of
siRNA and peptide for at least four hours (figure 2A). To
determine whether RVG-9r could deliver siRNA specifically to
AchR-expressing neuronal cells when complexed with liposomes,
we exposed LSPCs composed of either DyLight 488-labeled
RVG-9r or control RVM-9r peptide and increasing concentra-
tions of liposomes to N2a cells in the presence of 10% fetal bovine
serum (FBS). Control peptide RVM-9r in the absence of liposomes
failed to deliver PrP siRNA to N2a cells, while 1000 pmol of
liposomes in the PrP siRNA-RVM-9r complex facilitated siRNA
delivery to approximately 15% of N2a cells (figure 2B). RVG-9r
peptide complexed to PrP siRNA in the absence of liposomes
delivered siRNA to 8% of N2a cells, but increased to 12% when
complexed with 10 pmol liposomes, and to over 85% when
complexed with 100 pmol or more of liposomes. We used
equimolar concentrations of siRNA and liposomes in the
remainder of the experiments because this ratio produced the
highest cell specificity and protection from serum degradation.
Molar excesses of unlabeled RVG-9r, but not controlRVM-9r,
successfully competed against fluorochrome-tagged RVG-9r for
AchR binding in a time and dose dependent manner, confirming
RVG-9r specificity (figure 2C).
To confirm cell specificity, Alexa 488-labeled PrP siRNA-RVG-
9r-containing LSPCs were incubated with several cell lines that
were then assayed for LSPC delivery by FACS. LSPCs were
delivered to 9065% of N2a cells with a mean fluorescence
intensity (MFI) of 296644, significantly more than to 6767% of
human embryonic kidney 293 cells (HEK 293 cells, figures 2D and
E, p=0.03) with a MFI of 74621 (p,0.01). LSPCs bound to less
than 5% of 4T1 breast cell carcinoma or HeLa cervical cell lines
with MFIs below 10, significantly less than either N2a or HEK 293
cells (p,0.01, n=5). Similarly, RVG-9r-containing LSPCs bound
to 9861% of brain cells with a MFI of 8265, significantly more
than to 23611% of kidney cells (figures 2F and G, p,0.01) with a
MFI of 1164( p ,0.01). RVG-9r LSPCs bound to less than 2% of
splenocytes and hepatocytes with MFIs approximating 1, signif-
icantly less than either brain or kidney cells (p,0.01, n=3).
PrP siRNA-RVG-9r LSPC delivery kinetics
We monitored LSPC delivery to N2a cells over time by
fluorescent microscopy and FACS analyses to better understand
LSPC delivery kinetics. Merged color images reveal LSPC
deposition on cells beginning 1 h after incubation (figure 3,
compare panels a–d to e–h) that appears increased 4 h later (i–l),
Table 1. PrP 3’ UTR DNA target and delivery peptide
sequences.
plasmid
1 sequence
2
p1578 GAAGTAGGCTCCATTCCAAA
p1633 GGCAAAATTTGTTCCTGAAG
p1672 ACATAAACTGCGATAGCTTC
pControl
3 TCAAAATGTCGTCGTAAGAG
peptide
RVG-9r
4 YTIWMPENPRPGTPCDIFTNSRGKRASNGGGGrrrrrrrrr
RVM-9r
4 MNLLRKIVKNRRDEDTQKSSPASAPLDGGGGrrrrrrrrr
1numbers indicate position of first nucleotide relative to the prnp ORF start site.
2DNA sequences read 5’ to 3’, protein sequences read N to C-terminus.
3scrambled 1672 sequence.
4lower case r denotes d-Arginine racemer.
doi:10.1371/journal.pone.0011085.t001
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LSPC dissociation at 20 h (m–p), with PrP siRNA appearing more
perinuclear, where mRNA silencing occurs [36]. FACS analysis at
24 h indicates LSPCs containing RVG-9r peptide substantially
increased siRNA delivery to N2a cells over LSPCs containing
control RVM-9r peptide or liposomes alone (figure 3q). Cumu-
lative data from five separate experiments shows RVG-9r peptide
delivered PrP siRNA to 85610% of N2a cells with a MFI of
200631 (figure 3r), significantly more than RVM-9r peptide
(764% with an MFI of 563) or liposome alone (2064% with an
MFI of 1062, p,0.01), values not significantly different than
untreated cells (grey square, 362%, MFI of 362).
PrP-RVG-9r LSPCs suppress PrP
C expression
We next investigated whether PrP LSPCs could effectively
suppress PrP
C expression. LSPCs were formed and exposed to
N2a cells, which were analyzed for siRNA delivery and PrP
C
expression 48 h later. LSPCs containing RVG-9r (figures 4i–l), but
not RVM-9r (figures 4e–h) or liposomes alone (figures 4a–d),
delivered siRNA that could be visualized directly by fluorescent
microscopy. Merged images (figures 4d, h, l and p) reveal
substantial PrP
C expression in all treatment groups except N2a
cells treated with RVG-9r-PrP siRNA-containing LSPCs, where
PrP
C expression appeared significantly diminished, especially on
cells with Alexa 488-labeled PrP siRNA still evident (figures 4m–p).
FACS analysis of treated cells indicates reduced expression of PrP
C
on cells treated with PrP-RVG-9r LSPCs, with little or no
change in PrP
C expression on cells treated with PrP-RVM-9r
LSPCs, control-RVG-9r LSPCs or liposomes alone (figure 4q).
Quantification of data from at least five independent experiments
(figure 4r) revealed that PrP-RVG-9r LSPCs significantly de-
creased both the proportion of PrP
C-positive cells (7069%) and
the PrP MFI (2067) on N2a cells (p,0.01). All other groups
expressed PrP
C on greater than 85% of cells with MFIs
approximating 100. Cumulative data analysis shows that PrP-
RVG-9r LSPCs significantly decreased PrP
C expression on N2a
cells to 3068% (figure 4s, p,0.01) relative to N2a cells treated
with PrP-RVM-9r LSPCs (9963%), RVG-9r-control LSPCs
(9862%) or liposomes alone (9962%) or containing PrP siRNA
without peptides (8865%). While RVG-9r LSPCs efficiently
delivered PrP siRNA to HEK293 cells, they failed to suppress
PrP
C expression (data not shown). The 39 UTR in the human
PRNP gene does not contain the PrP siRNA target sequence, and
HEK 293 cells thus serve as an additional negative control for PrP
siRNA-specific suppression of murine PrP
C. Taken together, these
data demonstrate effective delivery of siRNA to N2a cells using
RVG-9r LSPCs and specific suppression of murine PrP
C
expression when these LSPCs delivered PrP siRNA.
PrP LSPCs eliminate PrP
RES in vitro
To ascertain whether LSPC knockdown of PrP
C expression
sufficed to cure prion infection, we used two cell culture models of
prion infection. N2a and NCerP cells were infected with the Rocky
Mountain Lab strain of mouse-adapted scrapie prions (RML) and
E2 CWD prions, respectively, and highly susceptible clones
isolated, expanded, and aliquots frozen as previously described
[37]. Prion-infected N2a and NCerP cells were passaged ten times,
at which time they were treated with LSPCs one time then grown
Figure 1. Transfection of shRNA plasmids effectively suppresses PrP
C mRNA transcript and protein levels in murine N2a cells. (A)
Schematic showing the relative locations of the target sequences in the 39 untranslated region of the murine prnp locus. Black, dotted and grey
arrows designate target sequences of p1578, p1633 and p1672, respectively. (B) Quantitative RT-PCR shows the relative mRNA expression in N2a cells
transfected with the indicated amounts of p1578 (black bars), p1633 (checkered), p1672 (grey), pControl (stippled) and empty vector (striped) relative
to untransfected control cells (white). (C) FACS analysis of cell-surface PrP
C expression in transfected cells. Peak fill colors correspond to the bar colors
shown in (B). The light grey peak represents unstained control cells. (D) Cumulative FACS data analysis. Bar colors correspond to the same sample
groups shown in (B). All three shRNA plasmids reduced PrP
C transcript (B) and protein (C and D) expression in N2a cells in a dose-dependent manner.
Data from each assay were collected from at least three independent experiments.
doi:10.1371/journal.pone.0011085.g001
LSPCs Inhibit Prion Infection
PLoS ONE | www.plosone.org 3 June 2010 | Volume 5 | Issue 6 | e11085Figure 2. Liposome protection and peptide delivery of PrP siRNA to neuronal cells. (A) 100 pmol of PrP siRNA was incubated with the
indicated amounts of liposomes then 1000 pmol of RVG-9r peptide. These siRNA-liposome-peptide complexes (LSPCs) were incubated at 37uC in the
presence of 90% freshly isolated mouse serum for the indicated times then electrophoresed through a 2% agarose gel. The arrowhead indicates free
siRNA and the arrow indicates siRNA-peptide complexes. Lane 8 contains an RNA molecular weight marker (bottom band is 100 bases). (B) 100 pmol
of Alexa 488-labeled of PrP siRNA was incubated with 100 pmol of liposomes then 1000 pmol of RVG-9r or RVM-9r. LSPCs were added to N2a cells for
four hours in the presence of media containing 10% FBS. Cells were harvested then analyzed by FACS. The black peak represents PrP siRNA
complexed with control peptide RVM-9r in the absence of liposomes; dark grey peak, PrP siRNA-RVM-9r complex plus 1000 pmol liposomes; white
peak, PrP siRNA-RVG-9r complex in the absence of liposomes; checkered peak, PrP siRNA-RVG-9r complexed with 10 pmol liposomes; stippled peak,
PrP siRNA-RVG-9r with 100 pmol liposomes; striped peak, PrP siRNA-RVG-9r with 1000 pmol liposomes. (C) Competitive binding experiment using
excess unlabeled RVG-9r or RVM-9r peptide against DyLight 488-labeled RVG-9r binding to N2a cells, varying either dose (left column) or time (right
column) in the presence of 100 pmol liposomes. (D) Representative FACS analysis of DyLight 488-labeled RVG-9r-containing LSPCs binding to N2a
(checkered peak), HEK (white peak), 4T1 (dark grey) or HeLa (black) cells. (E) Cumulative data analysis of RVG-9r LSPCs binding to N2a (checkered
circle), HEK293 (white circle), 4T1 (dark grey triangle) and HeLa (black square) cells. Representative FACS (F) and cumulative data (G) analyses of RVG-
LSPCs Inhibit Prion Infection
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each treatment group were collected at each passage and assayed
for PrP
RES. We detected no scrapie PrP
RES (PrP
Sc) in RML-
infected cells treated with PrP-RVG-9r LSPCs after passage 14
(figures 5A and E). We failed to detect even minute amounts of
residual PrP
Sc in these cells through an ultrasensitive prion
amplification technique called serial protein misfolding cyclic
amplification (sPMCA, Figure 5B [38,39]), while we detected
significant PrP
Sc in control-treated cells at passage 18 with or
without sPMCA. Similarly, we detected no CWD PrP
RES
(PrP
CWD) in CWD-infected cells treated with PrP-RVG-9r siRNA
after passage 12, while we detected PrP
CWD in control-treated cells
as far as passage 18 (figures 5C, D and F). Previous studies on these
prion strains revealed that PMCA can amplify serial dilutions of
RML and E2 two to three orders of magnitude per round ([38,40]
and our unpublished data), or a 10
212 to 10
218-fold dilution after
six PMCA rounds. These data convincingly demonstrate that PrP
LSPCs can sufficiently knockdown PrP
C expression to decrease
prion infection beyond delectability in two distinct cell culture
models.
LSPC delivery to PrP
C-expressing cells in vivo
Finally, we assessed the ability of RVG-9r LSPCs to protect and
deliver siRNA specifically to neuronal cells in live animals. LSPCs
containing 4 nmol of siRNA and liposomes and 40 nmol of
peptide were injected into the tail veins of FVB mice and LSPC
Figure 3. PrP siRNA-RVG-9r LSPC delivery kinetics. N2a cells were visualized before (panels a–d) or 1 h (e–h), 4 h (i–l) and 20 h (m–p) after
incubation with LSPCs containing DyLight 649-labeled RVG-9r (a, e, i and m) and Alexa 488-labeled PrP siRNA (b, f, j and n). Cell nuclei were visualized
with DAPI (c, g, k and o). (q) FACS analysis at 24 h of N2a cells treated with LSPCs containing PrP siRNA and RVG-9r (red dots) or control RVM-9r (black)
peptides or liposomes alone (green). Grey dots represent untreated cells. (r) Cumulative data from five separate delivery experiments. The red circle
represents data from N2a cells treated with RVG-9r and PrP siRNA-containing LSPCs; black square, PrP-RVM-9r LSPCs; green triangle, liposomes alone.
Grey square, untreated cells.
doi:10.1371/journal.pone.0011085.g003
9r LSPCs binding to brain (checkered peak (F) and circle (G)) and kidney (white peak and circle) cells, splenocytes (dark grey peak and triangle) and
hepatocytes (black peak and square). The light grey peaks in B, C, D, and F indicate unstained controls.
doi:10.1371/journal.pone.0011085.g002
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PLoS ONE | www.plosone.org 5 June 2010 | Volume 5 | Issue 6 | e11085Figure 4. PrP LSPCs suppress PrP expression. N2a cells treated with liposomes alone (panels a–d), or LSPCs containing Alexa 488-labeled
siRNAs, including RVM-9r control peptide and PrP siRNA (e–h), RVG-9r peptide and control siRNA (i–l) or RVG-9r and PrP siRNA (m–p). Cells were
harvested 48 hours later and stained with DyLight 649-labeled anti-PrP antibody (panels a, e, i and m). Cell nuclei were visualized with DAPI (c, g, k
and o). Inset in panel (i) depicts a serial section stained with an irrelevant isotype control antibody. (q) FACS analysis of N2a cells treated with PrP-
RVG-9r (red dots), PrP-RVM-9r (blue), or RVG-9r-control siRNA (green) LSPCs or liposomes alone (black). Grey dots represent untreated, unstained N2a
cells. (r) Quantification of data from at least five independent experiments. Red circle represents N2a treated with PrP-RVG-9r LSPCs; green circle,
control- RVG-9r LSPCs; blue triangle, PrP-RVM-9r LSPCs; black square, liposomes alone; grey square, untreated and unstained N2a cells. (s) Cumulative
data comparing relative PrP
C expression on N2a cells treated with liposomes alone (grey bar), PrP-RVM-9r (blue), control-RVG-9r (green) or PrP-RVG-9r
(red) LSPCs or PrP siRNA and liposomes only (orange). Symbols associated with each bar indicate values for five independent experiments.
doi:10.1371/journal.pone.0011085.g004
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PLoS ONE | www.plosone.org 6 June 2010 | Volume 5 | Issue 6 | e11085Figure 5. PrP LSPCs cure prion-infected cells in vitro. Chronically-infected N2a (A and B) and NCerPrP (C and D) cells were treated for 72 h with
PrP-RVG-9r (PG, lanes 3–7), control-RVG-9r (CG, lane 8), or PrP-RVM-9r LSPCs (PM, lane 9) or liposomes alone (Lip, lane 10). Cells were split at the
indicated passage and excess cells pelleted, digested with 10 mg/mL proteinase K, electrophoresed and immunoblotted for PrP
RES. Negative samples,
and one positive sample diluted 1000-fold, from each infection were subjected to six 48-cycle rounds of PMCA (B and D). Molecular weight markers
are shown for 20, 30 and 40 kilodaltons to the left of each blot. (E and F) Densitometric analyses of western blots from three independent
experiments treating prion infection in both N2a (E) and NCerPrP (F) cells. Black circles connected by solid lines represent cells treated with PrP-RVG-
LSPCs Inhibit Prion Infection
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FACS. Merged color images reveal strong PrP staining in the
cerebellum, where significant prion neuropathology has been
previously documented [38,41]. PrP staining was particularly
strong in white matter tracts and the molecular layer but also
evident in the granular layer (Figures 6d, e, i, j, n, o, s and t).
Liposomes alone (figures 6a–e) or the RVM-9r peptide (figures 6f–j)
delivered little or no siRNA, while the RVG-9r peptide delivered
easily detectable amounts of siRNA to areas that appear to overlap
with PrP
C expression (figures 6k–t). FACS analyses demonstrate that
RVG-9r delivered siRNA to 9363% of brain cells with a MFI of
40618 (figure 6u and v), to significantly less kidney cells (1663%
with a MFI of 1665), splenocytes and hepatocytes (both less than
3 % ,w i t hM F I sl e s st h a n3 ,p ,0.01, n=5), approximating values for
liposome-only controls (261%, MFI=2.561, n=4). RVG-9r
delivery of PrP siRNA correlated with reduced numbers of PrP-
expressing brain cells (figure 6w and x, 6369%) and PrP MFI
(90627, n=3) compared to cells treated with liposomes alone
(9562%, MFI=150637), RVM-9r- PrP siRNA (9565%,
MFI=202619, n=2) and RVG-9r-control siRNA (8467%,
MFI=369677, n=2). Somewhat surprisingly, after just 24 hours,
brain cells from PrP-RVG-9r LSPC-treated mice (n=3) reduced
PrP
C expression to approximately 75611% (figure 6y) relative to all
control groups combined (p,0.05, n=8). These data indicate
specific delivery of significant amounts of PrP siRNA to PrP
C-
expressing cells using RVG-9r LSPCs.
Discussion
The efficacy of reducing PrP
C expression to delay or even
reduce prion disease and neuropathology has been established
[11,12,13,14]. Several recent studies have demonstrated the
potential of using PrP-specific shRNAs encoded by lentiviral
constructs injected ic to knock down PrP
C expression [12,13].
Several aspects of this method limit its efficacy. Poor transport
across the BBB dictates delivery by stereotactic injection of PrP
shRNA lentivirus directly into the brain. Even then, viral infection
and shRNA expression was limited to a small area around the
injection site, resulting in spatially limited suppression of PrP
C
expression, modestly impeded disease progression and unaltered
disease incidence. This method also lacks desired temporal control
of PrP
C expression, since once brain cells are infected with
lentivirus, it will likely irreversibly suppress PrP
C expression in
these cells. Moreover, despite improvements in lentiviral vector
technology and construction [42,43,44,45,46], concerns over the
oncogenic capacity of lentiviral delivery systems remain [47].
Another group created transgenic mice stably expressing PrP
shRNA that reduced PrP
C expression five-fold, although they did
not assess prion disease in these animals [25]. This method
demonstrates an important proof-of-principle, but suffers from the
same irreversibility of PrP
C suppression as lentiviral shRNA
delivery, and transgenesis is not a viable therapeutic option.
In this study, we have begun to explore the possibility of using
LSPCs injected iv to deliver PrP
C siRNA across the BBB to all
areas of the brain to suppress PrP
C expression on neurons to
protect them from prion diseases. RVG-9r, a modified peptide
from the rabies virus glycoprotein that acts as a ligand for AchRs
and whose positively charged Arginine tail binds the negatively
charged phosphate backbone of siRNAs, has been shown to
effectively target siRNA to neuronal cells when delivered through
the vascular system to the CNS [26]. We postulated that RVG-9r
could act as a molecular address for PrP siRNA as well and used it
as such in experiments described here.
In order for siRNA injections to be useful in treating prion
diseases, serum degradation must be prevented during vascular
transport. Kumar reported only partial protection of siRNA by
RVG-9r from serum degradation. Zimmerman found more than a
100-fold improvement in gene silencing when siRNA was
complexed to lipids [34]. Other studies have also shown that
serum half-life is greatly improved when siRNA is encapsulated
within a liposomal nanoparticle [23,32]. Taken together, these
studies indicate that liposomes increase the stability of the siRNA-
peptide complex in serum leading to increased treatment efficacy.
After identifying suitable RNAi targets in the 39 UTR of the prnp
gene and synthesizing cognate siRNAs, we tested the ability of
cationic liposomes to protect them and the RVG-9r peptide from
serum degradation. One hundred pmol of liposomes maximally
protected LSPCs from degradation after 4 hours of incubation in
mouse serum. We also found that LSPCs increased the siRNA
binding to N2a cells in a dose-dependent manner, presumably by
protecting siRNA-RVG-9r complexes, thereby increasing their
bioavailability. Interestingly, 1000 pmol of liposomes decreased
LSPC protection and specificity in our assay. Perhaps excess
liposomes encapsulated protease and nuclease-laden serum and
fused to LSPCS, degrading them over time, Indeed, 1000 pmol of
liposomes nonspecifically delivered LSPCS to cells, indicating that
excess liposomes may be fusing with cell membranes, supporting
this interpretation. We therefore used equimolar amounts of
liposomes and siRNA for subsequent experiments.
Our in vitro experiments show the specificity of RVG-9r LSPCs
for N2a and HEK 293 cell lines, as well as primary neuronal cells
and a small proportion of primary kidney cells, but not to HeLa or
4T1 breast carcinoma cell lines or primary splenocytes or
hepatocytes. Control RVM-9r LSPCs did not bind to any of
these cell types. HEK 293 cells, created by transformation of
primary HEK cells with the preferentially neurotropic Ad5 virus,
express many neuronal proteins, including AchRs, and are likely
of neuronal lineage [48,49]. The inner medullary collecting duct
cells of the kidney also express AchRs [50,51]. These LSPC
binding results expand on those demonstrating RVG binding to
N2a cells, but not HeLa cells or 293T cells, created by
transformation of HEK cells with the SV40 T antigen, and
distinct from the HEK 293 cells that we used [49]. Both HeLa and
293T cells have been shown to lack AchRs[26], and several
microarray analyses have failed to demonstrate AchR expression
in 4T1 cells [52,53,54], consistent with lack of RVG binding to
them. RVG-9r LSPCs were delivered to AchR-expressing cells in
as little as one hour, with LSPC dissociation and siRNA
movement to the perinuclear space by twenty hours after
treatment.
We further show that AchR-expressing neuronal cells specifi-
cally targeted by RVG-9r LSPCs also express PrP
C, which was
suppressed 70% by PrP siRNA LSPCs 48 hours after treatment.
Reduced, punctate staining of cell-surface PrP
C suggests an
impaired ability to replace older PrP
C being removed by normal
cell membrane turnover and/or protein recycling with nascent
PrP
C, whose synthesis is greatly inhibited by LSPCs.
A single treatment with PrP siRNA-RVG-9r LSPCs decreased
the amount of PrP
SC and PrP
CWD formation to undetectable levels
in chronically prion-infected infected cultures of N2a and NCerP
9r LSPCs; open squares connected by solid lines, Control-RVG-9r LSPCs; black squares connected by dashed lines, PrP-RVM-9r LSPCs; and black
triangles connected by dotted lines, Liposomes alone.
doi:10.1371/journal.pone.0011085.g005
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still contained PrP
Sc after 18 passages. We also subjected cured cell
lysates to six rounds of serial PMCA and detected no PrP
RES.W e
have successfully detected up to a 10
218-fold dilution of RML and
E2 prions using PMCA, which is far more sensitive than N2a cell
culture assays, which can replicate PrP
Sc from RML dilutions up
to 10
28 to sustain prion infection [37,55,56]. We therefore
conclude that PrP siRNA-RVG-9r LSPCs dramatically decreased
prion infection beyond sustainable levels in two cell culture
models.
Kim et al recently reported that stable transfection of PrP
shRNA plasmids into ScN2a cells chronically infected with Syrian
hamster prions [57] initially cleared prion infection below
detection but failed to clear all PrP
Sc, as evidenced by a recurrence
of PrP
Sc by further passage or PMCA of cell pellets [58].
Differences in prion strains, infection protocols and host cell clones
may account for differences among these three studies. Impor-
tantly, though, RNAi treatment in all of these model systems
dramatically impeded PrP
RES replication by reducing PrP
C
expression by more than 50%, an expression threshold shown to
dramatically delay disease onset [11,12,13,14]. Genetic or siRNA-
mediated PrP
C depletion in these studies delayed or even
prevented disease, while still replicating PrP
Sc to levels seen in
wild type mice expressing normal levels of PrP
C. Therefore, the
presence of PrP
RES may not reliably predict disease incidence and
severity in vivo. Transient, partial PrP
C knockdown may
sufficiently arrest disease progression such that treated patients
may live normal life spans with reduced pathology and clinical
symptoms, albeit with potentially significant PrP
RES accumulation.
RNAi therapy using lentiviral delivery exhibited marginal
efficacy in ameliorating disease and pathology in previous in vivo
prion disease models, most likely because direct ic injection limited
viral transduction to cells immediately adjacent to the injection site
[12,13]. We sought to improve PrP siRNA delivery via iv
administration of LSPCs. Many cells in the brain that are
important in prion pathogenesis express AChRs, including
neurons, astrocytes and microglia [59]. Following iv injection of
fluorescent RVG-9r LSPCs into FVB mice, we found many
labeled cells throughout the brain that also expressed PrP
C,
indicating that PrP siRNA can be delivered across the BBB to
PrP
C-expressing neuronal cells by a AchR-binding peptide.
A previous study demonstrated transvascular delivery of GFP-
labeled siRNA to the CNS using the RVG-9r peptide alone [26].
However, FITC-labeled siRNA was directly visible in only a
fraction of the brains from treated mice, with most requiring an
additional anti-FITC staining to visualize the siRNA. We detected
fluorescent siRNA in all mice treated with RVG-9r LSPCs without
a secondary stain, suggesting that LSPCs protected siRNA-peptide
complexes from significant serum degradation, facilitating delivery
of more siRNA that was directly visible in the brain 24 hours after
iv injection. However, we also used fluorescent RVG peptide
emitting at the same wavelength as PrP siRNA to enhance
detection that was problematic in previous studies. So using both
488 nm-fluorescent peptide and RNA likely contributed to our
increased sensitivity. In either case, our study demonstrates
effective delivery of siRNA to the brain using LSPCs.
While we designed this experiment to test RVG-9r LSPC-
mediated PrP siRNA delivery to PrP
C-expressing neurons, we also
observed a significant decrease in PrP
C expression on CNS cells
after just 24 hours post treatment. We detected insignificant
amounts of RVG-9r LPSCs binding to non-neuronal cells, which
is important in both focusing treatment and limiting potential side
effects of siRNAs. These experiments build on previous ones
demonstrating GFP and SOD1 gene silencing only in the brain
following iv administration of RVG-9R siRNA to GFP transgenic
and wild type Balb/c mice, respectively [26]. Intravenous
treatment with siFvE + RVG-9R was also able to protect 80%
of inoculated mice from fatal flaviviral encephalitis. The RVG-9r
peptide elicited no adverse inflammatory or other immune
response in treated mice, which exhibited no adverse side effects
and appeared to tolerate the treatment very well. Our system
involves the addition of cationic liposomes to siRNA-RVG-9r
complexes. Cationic liposomes carrying plasmid or CpG DNA
have been used as adjuvants to specifically enhance immunity
against infection and tumors [60,61,62,63]. We carefully screened
siRNA sequences to specifically avoid the Interferon response
[64,65] and used liposome concentrations well below those used as
adjuvants to prevent immunogenicity. We also constructed LSPCs
fifty times smaller than microparticles shown to become trapped in
lung tissue [66]. Indeed, we saw no evidence of LSPC uptake by
immune cells such as macrophages and dendritic cells in the
spleen, and observed no evidence of lung pathology in treated
mice. However, further in vivo studies need to confirm that LSPCs
do not elicit potentially harmful immune responses.
We envision LSPC therapy to be a new delivery system that
greatly enhances the capacity of PrP siRNA to transiently suppress
PrP
C expression in nearly every neuron in the CNS that will
significantly impede prion replication and disease progression.
Whether therapy can rescue patients already exhibiting clinical
signs of prion disease must be determined. The most effective
therapy, however, will be coupled with improved diagnostic
techniques that allow the earliest possible detection of prion
diseases, including early behavioral and cognitive tests currently
being developed [13,67,68].
LSPC therapy targeting host protein expression may also
benefit other protein misfolding disorders. For example, PrP
C has
been shown to bind Amyloid-b oligomers and mediate synaptic
dysfunction in hippocampal slice cultures, suggesting a potential
role for PrP
C in Alzheimer’s disease [69]. LSPCs targeting PrP
C,
perhaps in combination with Amyloid Precursor protein expres-
Figure 6. LSPC delivery to PrP
C-expressing cells in vivo. FVB mice were intravenously injected with liposomes alone (panels a–e) or LSPCs
containing DyLight 488-labeled peptides and Alexa 488-labeled siRNAs as follows: PrP-RVM-9r (f–j), Control-RVG-9r (k–o), or PrP-RVG-9r (p–t). Mice
were sacrificed 24 hours later, dissected, and their brains snap frozen and 8 mm sections thereof stained with DyLight 649-labeled anti-PrP antibody
(a, f, k and p) and DAPI (c, h, m and r) and visualized by fluorescence microscopy. Panels d, f, m and s are labeled to show the granular and (g)
molecular (m) layers and white matter tracts (w), Panels e, j, o and t depict magnifications of the granular layer and white matter boundary in the
boxed areas in panels d, i, n and s. Inset in panel p depicts a serial section stained with an irrelevant isotype control antibody. Scale bars, 50 mm for all
panels except e, j, o and t, which is 10 mm. (u and v) FACS analysis of PrP-RVG-9r LSPC delivery to brain cells (checkered peak (u) and circle (v)), kidney
cells (white peak and circle), splenocytes (dark grey peak and triangle) and hepatocytes (black peak and square). The light grey peak (u) and square (v)
depict PBS-treated, unstained control brain cells. (w and x) FACS analysis of PrP
C expression on brain cells treated with PrP-RVG-9r (red dots (w) and
circle (x)), RVG-9r-control (green dots and circle), PrP-RVM-9r (blue dots and triangle) LSPCs, or liposomes alone (black dos and square). The grey dots
and square depict untreated, unstained brain cells. (y) Cumulative data showing relative PrP expression on brain cells treated with liposomes alone
(grey bar) or with LSPCs containing PrP-RVM-9r (blue), control-RVG-9r (green) or PrP-RVG-9r (red). Symbols associated with each bar indicate values
for individual mice.
doi:10.1371/journal.pone.0011085.g006
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Methods
Mice
FVB mice were purchased from Charles River (Wilmington,
MA) and maintained and handled in strict accordance with good
animal practice as defined by relevant national and/or local
animal welfare bodies, and all animal work was approved by
Colorado State University Institutional Animal and Care Use
Committee (IACUC approval numbers 08-146ABC-02 and 08-
281A-02).
Cell lines and culture
N2a, HEK 293, HeLa and 4T1 cells were purchased from
ATCC (Manassas, VA). NCerP cells are a derivation of N2a cells
that express cervid PrP
C instead of mouse PrP
C (our unpublished
data). Briefly, we enriched for N2a cells lacking endogenous PrP
C
expression (ND cells) by five rounds of fluorescence activated cell
sorting (FACS) and clonal expansion. Lipofectamine 2000 reagent
was used according to manufacturer’s protocol (Invitrogen) to
transfect ND cells with a 1:10 ratio of a plasmid encoding the
neomycin resistance gene and the PrP half genomic construct [70]
in which the murine PrP ORF was replaced by the cervid PrP
ORF from mule deer. G418-resistant clones were selected and
cervid PrP expression confirmed by FACS (data not shown). Cell
lines were maintained in RPMI media supplemented with 10%
fetal bovine serum (FBS), 100 U/mL Penicillin and 100 mg/mL
Streptomycin (1X Pen-Strep, GIBCO). Primary cells were
harvested from brain, spleen, liver and kidney of FVB mice and
passed through a 45 mm nylon mesh to create single cell
suspensions in RPMI, 10% FBS, 1X Pen-Strep.
RNAs
PrP 39 untranslated region (UTR) DNA target and control
sequences (table 1, GenBank accession number NM_011170) were
identified using siRNA scales [35]. Plasmids encoding shRNA
targeting these sequences were constructed using oligonucleotides
synthesized, purified, annealed and cloned first into the pENTR/
D-TOPO plasmid and then subcloned into the pBLOCK-iT 3-
DEST Vector plasmid using the Gateway cloning system
according to the manufacturer’s protocol (Invitrogen, Carlsbad,
CA). A 4-base 59-CGAA-39 loop was inserted between the
complimentary sequences encoding the shRNAs. Duplex siRNAs
targeting the same sequences and AllStars negative control siRNAs
were synthesized, purified, annealed and resuspended in RNase-
free water and, where indicated, labeled with Alexa 488 on the 59
sense strand (Qiagen, Valencia, CA).
Peptides and liposomes
Peptides RVG-9r and RVM-9r (table 1) were previously
described [26] and synthesized, purified by high performance
liquid chromatography (Pi Proteomics, Huntsville, AL) and
resuspended in sterile 1X PBS. Where indicated, peptides were
labeled with DyLight 488 or 649 fluorochromes according to
manufacturer’s protocol (Pierce, Rockford, IL). Liposomes were
prepared as previously described [63] with slight modifications.
Briefly, equimolar concentrations of the cationic lipid octadece-
nolyoxy[ethyl-2-heptadecenyl-3 hydroxyethyl] imidazolinium
chloride (DOTIM, Sigma-Aldrich, St. Louis, MO) and cholesterol
(Avanti Polar Lipids, Alabaster, AL) in chloroform were added to
round-bottom, 15-mL glass tubes to a final concentration of
2 mM. The solution was then dried overnight in a vacuum
desiccator to a thin film. Liposomes were rehydrated to a final
concentration of 10 mM in 10% sucrose in water at 50uC for
50 min, followed by incubation for 2 h at room temperature and
serially filtered through 1, 0.45 and 0.2 mM pore filters (Pall Life
Sciences, Port Washington NY) to achieve uniform size and
sterility then stored under argon at 4uC. Liposomes were sonicated
3640 s at 70% maximum power in a MP4000 horn sonicator
(Misonix) then diluted to working concentrations immediately
prior to use.
Plasmid transfection and PrP
C mRNA and protein
analyses
shRNA plasmids were transfected into 10
5 N2a cells at the given
concentrations using Lipofectamine 2000 transfection reagent
(Invitrogen). Cells were harvested 48 hours later and analyzed for
PrP
C mRNA and protein expression. mRNA was isolated using
the Oligotex Direct mRNA mini kit reverse-transcription
polymerase chain reaction (RT-PCR) performed in real-time
using QuantiTect SYBR Green RT-PCR Kit (Qiagen). PrP
transcripts were amplified in an iCycler RT-PCR machine (Bio-
Rad, Hercules, CA) using the forward primer 59- CCT TGG
TGG CTA CAT GCT GG-39 and reverse primer 59-GGC CTG
TAG TAC ACT TGG-39. DNA templates were pre-melted at
95uC for five minutes; then amplified for thirty cycles of melting at
95uC for one minute, primer annealing at 50uC for thirty seconds
and amplicon elongation at 72uC for one minute; followed by one
final elongation cycle at 72uC for five minutes. Cycle threshold
values were determined automatically by iCycler software and
normalized by those for b-actin transcripts amplified using the
Mm_Actb_2_SG QuantiTect Primer Assay (Qiagen). Amplicon
specificity was determined by melting curve analysis and
confirmed by agarose gel electrophoresis (data not shown). PrP
mRNA expression was reported relative to that for untreated N2a
cells.
Fluorescence Activated Cell Sorting (FACS)
For protein analysis, 10
6 transfected and control N2a cells were
washed three times with FACS buffer (10 mM EDTA, 0.1% fetal
bovine serum in 1X PBS), incubated for ten minutes in 10%
mouse serum in FACS buffer, stained with 1:100 dilution of
DyLight 649-labeled Bar224 (SPI Bio) in 100 ml of FACS buffer
supplemented with 5% mouse serum for thirty minutes, washed
three times with FACS buffer, resuspended in 1 mL FACS buffer
and analyzed using a Cyan multicolor flow cytometer (Dako
Cytomation). PrP
C expression was reported relative to that for
untreated N2a cells.
Liposome protection assay
100 pmol of siRNA was incubated with 0, 10, 100 or
1000 pmol of liposomes at room temperature and 1000 pmol
RVG-9r peptide was added ten minutes later. Five microliters of
the siRNA-liposome-peptide complexes (LSPCs) were added to
45 ml of freshly isolated mouse serum. Samples were incubated at
37uC and 10 ml aliquots removed at 0, 1, 2 and 4 hours and
electrophoresed through a 2% agarose gel stained with ethidium
bromide. Bands were visualized and digitally photographed using
the LAS 3000 gel documentation system (Fuji).
LSPC formation
100 pmol of PrP or control siRNA was incubated with
100 pmol of liposomes at room temperature and 1000 pmol of
RVG-9r or RVM-9r peptide was added ten minutes later.
Liposome size and charge were estimated using a Brookhaven
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(Brookhaven Institute, Holtsville, NY).
LSPC delivery and PrP
C silencing in vitro
1 mL of cell culture medium without antibiotics was added to
the LSPCs, which were added to 10
5 transformed or 10
6 primary
cells five minutes later. Fluorochrome-labeled LSPCs were
prepared and used as indicated. Additional control cells received
media lacking any of the 3 LSPC components. All cells were
incubated at 37uC for 1–4 h. Cells were either harvested and
analyzed for peptide binding, siRNA delivery and/or PrP
C
expression; or supplemented with an additional 1 mL of cell
culture media with antibiotics and incubated an additional 16–
44 h before analyses. For peptide competition experiments, the
indicated molar excess of unlabeled peptide was added to cells
suspended in FACS buffer for the indicated times, then analyzed
by FACS.
Prion infection of neuronal cell lines
N2a and NCerP cells were infected with the Rocky Mountain
Lab strain of mouse-adapted scrapie prions and E2 CWD prions,
respectively, as previously described [37] with slight modifications.
Briefly, prion-containing brain homogenates were incubated with
50 mg/mL protease K (PK) for thirty minutes at 37uC, ten minutes
at 95uC and then on ice for five minutes. 10
5 cells were pelleted
then resuspended in 100 mlo fa1 0
23 dilution of prions for thirty
minutes at room temperature, diluted into 1 mL RPMI medium,
10% FBS and 1X Pen-Strep and incubated at 37uC in each well of
a 12-well plate until confluent, then split 1:3. Confluent cells were
split 1:3 twice more, 1:10 three times, then analyzed for PrP
RES by
PK digestion and western blotting (WB) as previously described
[38]. Three positive wells from each cell line were expanded and at
least ten 5610
6-cell aliquots stored in liquid nitrogen.
LSPC treatment of prion infected cells in vitro
LSPCs were complexed as described and delivered to 10
5
infected cells passaged ten times. Cells were grown to confluency
and split 1:10 an additional eight times. 90% of cells at each
passage were pelleted and assayed for PrP
RES by PK digestion and
WB. Twenty-five microliters of samples lacking PrP
RES and one
PrP
RES+ sample diluted 1000-fold were subjected to six rounds of
protein misfolding cyclic amplification (PMCA), PK digestion and
WB as previously described [40].
Analysis of LSPC delivery in vivo
Four nanomoles of Alexa 488-labeled PrP or control siRNA was
incubated with 4 nmol of liposomes for twenty minutes at room
temperature and 40 nmol of DyLight 488-labeled RVG-9r or
RVM-9r peptide added ten minutes later. LSPC volumes were
increased to 300 ml with 1X PBS and injected into tail veins of
FVB mice. PBS alone was injected into additional control mice.
Mice were euthanized 24 hours later, dissected and brains,
spleens, livers and kidneys harvested for FACS analysis. An
approximately 1 mm coronal brain section through the midbrain
was used for FACS analysis, and the remainder was snap-frozen
on liquid nitrogen for immunofluorescence microscopy.
Immunofluorescent staining and microscopy
Where indicated, transformed and primary cells were stained
with DyLight 649-labeled Bar224 or POM-2 [71] anti-PrP
antibodies as described for FACS analysis. Nuclei were stained
with 100 ng/mL DAPI for ten minutes. 10
5 N2a cells were grown
and stained on cover slips and 10
6 primary cells stained in
eppendorf tubes and cytopsun onto glass slides.
For brain sections, 8 mm-thick cryosections were adhered to
glass slides, fixed for ten minutes in acetone and air-dried
overnight. Slides were incubated in a humidified chamber with
10% FBS and mouse serum for thirty minutes, a 1:100 dilution of
DyLight 649-labeled POM-2 for one hour and 100 ng/mL DAPI
for twenty minutes and washed 5X with PBS.
Slides were mounted with coverslips using ProLong Gold
antifade fluorescent mounting medium (Invitrogen) and dried at
room temperature overnight then at 220uC for 24 h. Cells and
sections were visualized and digitally photographed using a BX60
microscope equipped with a DP-71 charge-coupled diode (CCD)
camera (Olympus), or an Olympus IX71 microscope using Retiga
2000R CCD camera (Qimaging, Surrey, BC, Canada). Images
were acquired using slidebook software (Intelligent Imaging
Innovations, Inc., Denver, CO) on a Macintosh G5 dual processor
computer (Apple Computer).
Densitometric and statistical analyses
Densitometric analyses were performed on unsaturated western
blots using Quantity One software (Bio-Rad) as previously
described [40]. One-way ANOVA with Tukey post-test analysis
was performed using GraphPad Prism.
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